Pharma Pulse 11/12/24: Takeaways From Midlife MS Patients, The Power of Simplicity for First-in-Human Studies & more
Pharmaceutical Executive November 12, 2024
The latest news for pharma industry insiders.
Optimizing Clinical Trial Efficiency: The Power of Simplicity for First-in-Human Studies
How industry can increase the speed of these trials while continuing to meet patient needs.
The Takeaway From Study of Midlife MS Patients: Don’t Stop Disease-Modifying Therapy
People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop disease-modifying therapy have higher hospitalization rates and more visits to the emergency room.
From AI to Hardware Costs: Enterprise Tech Leaders Prepare for Trump 2.0
The president-elect’s focus on tariffs and reducing regulation could affect hardware costs and AI deployments, and set off an M&A frenzy, CIOs...